glp-1 in canada WHO backs meds to treat obesity, but many Islanders can't access them GLP-1 in Diabetes Care

Early studies suggest GLP-1 drugs may reduce cravings for alcohol, nicotine and opioids by modulating the brains reward pathways

10.1186/s12958-025-01447-3

Ozempic and alcohol

The GLP-1 is released upon food consumption in a biphasic pattern with an early phase 1015 min and a longer second phase 3060 min after meal

3.3 Mitochondrial dysfunction and oxidative stress Chronic hyperglycemia in patients with T2DM leads to peripheral insulin resistance, whereas impaired insulin signaling pathways in the brains of patients with AD lead to brain insulin resistance, both of which are closely related to mitochondrial dysfunction and OS (Du et al., 2022